FDA Grants RMAT Designation to Krystal Biotech's KB707 Gene Therapy for Advanced Non-Small Cell Lung Cancer
核心洞察
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, Krystal Biotech's inhaled immunotherapy targeting advanced or metastatic non-small cell lung cancer.
KB707 is designed as a redosable gene therapy that drives sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment.
Early clinical evidence from the ongoing KYANITE-1 study demonstrated consistent antitumor activity, including durable responses and clinically significant tumor reductions in heavily pre-treated patients.
Krystal Biotech announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the company's innovative gene therapy for treating advanced or metastatic non-small cell lung cancer (NSCLC). The designation recognizes both the urgent unmet medical need in NSCLC treatment and the promising early clinical evidence demonstrated by the inhaled immunotherapy.
Novel Gene Therapy Mechanism
KB707 represents a redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 directly in the tumor microenvironment. This approach aims to enhance immune response specifically at the tumor site while potentially minimizing systemic side effects associated with traditional immunotherapies.
"The FDA's decision to grant RMAT designation to KB707 reflects both the urgent unmet need for new NSCLC therapies as well as the promising early clinical evidence of efficacy we have observed with inhaled KB707 in patients with advanced NSCLC," said Suma Krishnan, President of Research and Development at Krystal Biotech.
Clinical Evidence Supporting Designation
The RMAT designation was supported by early clinical evidence from Krystal Biotech's ongoing KYANITE-1 study, which demonstrated consistent and meaningful antitumor activity in patients with heavily pre-treated advanced NSCLC receiving inhaled KB707. The study showed durable responses and clinically significant tumor reductions in this challenging patient population.
Enrollment in the KYANITE-1 study continues, with additional details expected to be presented at upcoming scientific conferences. The study is registered under NCT identifier NCT06228326 on ClinicalTrials.gov.
Regulatory Advantages and Development Path
The RMAT designation provides significant regulatory advantages that could accelerate KB707's path to market. The designation includes all benefits of the FDA's Fast Track and Breakthrough Therapy designations, offering potential for rolling review, intensive FDA guidance and interaction, and organizational commitment from senior FDA managers.
Additionally, the designation enables more frequent collaboration with the FDA to discuss innovative trial designs, surrogate or intermediate endpoints to support potential accelerated approval, and novel approaches to satisfy post-approval requirements.
This marks the second RMAT designation granted to a Krystal Biotech program, providing the company with valuable experience in leveraging these regulatory pathways. Krishnan noted that the company understands "first-hand the benefits that this designation can provide to accelerate development and shorten the path to a potential approval."
Company Background and Pipeline
Krystal Biotech operates as a fully integrated, commercial-stage global biotechnology company focused on genetic medicines for diseases with high unmet medical needs. The company's first commercial product, VYJUVEK®, represents the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for treating dystrophic epidermolysis bullosa.
The company is advancing a robust pipeline of investigational genetic medicines beyond KB707, positioning itself as a leader in the redosable gene therapy space. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, and trades on NASDAQ under the symbol KRYS.